Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 26, 2018 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference

SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
May 31, 2018 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference

SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
May 17, 2018 07:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference

SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
May 14, 2018 06:45 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring

SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
May 02, 2018 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Provides Mechanistic Update on Resokine Pathway at American Academy of Immunology Annual Meeting

SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
November 27, 2017 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)

– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN...
November 14, 2017 16:05 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
September 27, 2017 08:00 ET | Source: aTyr Pharma Inc.

aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society

SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
September 05, 2017 23:00 ET | Source: aTyr Pharma Inc.

aTyr Pharma to Present at Two Upcoming Investor Conferences in September

SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
August 28, 2017 07:30 ET | Source: aTyr Pharma Inc.

aTyr Pharma Announces $45 Million Equity Financing

SAN DIEGO, Aug. 28, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics, harnessing the...

Next Page keyboard_arrow_right